Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.

Ariës IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, Pfirrmann M, Degar J, Landrigan JT, Balbach S, Peirs S, Menten B, Isenhart R, Stevenson KE, Neuberg DS, Devidas M, Loh ML, Hunger SP, Teachey DT, Rabin KR, Winter SS, Dunsmore KP, Wood BL, Silverman LB, Sallan SE, Van Vlierberghe P, Orkin SH, Knoechel B, Letai AG, Gutierrez A.

J Exp Med. 2018 Nov 7. pii: jem.20180570. doi: 10.1084/jem.20180570. [Epub ahead of print]

PMID:
30404791
2.

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machová Poláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX; EURO-SKI investigators.

Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4.

PMID:
29735299
3.

Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis. A systematic review and meta-analysis.

Rupprecht TA, Manz KM, Fingerle V, Lechner C, Klein M, Pfirrmann M, Koedel U.

Clin Microbiol Infect. 2018 Apr 16. pii: S1198-743X(18)30342-2. doi: 10.1016/j.cmi.2018.04.007. [Epub ahead of print] Review.

PMID:
29674128
4.

Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.

Rinaldetti S, Pfirrmann M, Manz K, Guilhot J, Dietz C, Panagiotidis P, Spiess B, Seifarth W, Fabarius A, Müller M, Pagoni M, Dimou M, Dengler J, Waller CF, Brümmendorf TH, Herbst R, Burchert A, Janβen C, Goebeler ME, Jost PJ, Hanzel S, Schafhausen P, Prange-Krex G, Illmer T, Janzen V, Klausmann M, Eckert R, Büschel G, Kiani A, Hofmann WK, Mahon FX, Saussele S.

Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):266-271. doi: 10.1016/j.clml.2018.02.004. Epub 2018 Feb 8.

5.

PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.

Drube J, Ernst T, Pfirrmann M, Albert BV, Drube S, Reich D, Kresinsky A, Halfter K, Sorio C, Fabisch C, Hochhaus A, Böhmer FD.

Oncotarget. 2018 Jan 15;9(10):9442-9455. doi: 10.18632/oncotarget.24253. eCollection 2018 Feb 6.

6.

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

Saussele S, Hehlmann R, Fabarius A, Jeromin S, Proetel U, Rinaldetti S, Kohlbrenner K, Einsele H, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Oppliger Leibundgut E, Heim D, Krause SW, Hofmann WK, Hasford J, Pfirrmann M, Müller MC, Hochhaus A, Lauseker M.

Leukemia. 2018 May;32(5):1222-1228. doi: 10.1038/s41375-018-0055-7. Epub 2018 Feb 26.

7.

Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study.

Hummel S, Beyerlein A, Pfirrmann M, Hofelich A, Much D, Hivner S, Bunk M, Herbst M, Peplow C, Walter M, Kohn D, Hummel N, Kratzsch J, Hummel M, Füchtenbusch M, Hasford J, Ziegler AG; PINGUIN Study Group.

Mol Metab. 2018 Mar;9:168-175. doi: 10.1016/j.molmet.2017.12.015. Epub 2018 Jan 3.

8.

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Schütz C, Inselmann S, Saussele S, Dietz CT, Müller MC, Eigendorff E, Brendel CA, Metzelder SK, Brümmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Mahon FX, Pfirrmann M, Burchert A.

Leukemia. 2018 Apr;32(4):1054. doi: 10.1038/leu.2017.348. Epub 2018 Jan 30.

PMID:
29381150
9.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, Neubauer A, Hossfeld DK, Nerl C, Gratwohl A, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Müller MC, Jeromin S, Proetel U, Kohlbrenner K, Voskanyan A, Rinaldetti S, Seifarth W, Spieß B, Balleisen L, Goebeler MC, Hänel M, Ho A, Dengler J, Falge C, Kanz L, Kremers S, Burchert A, Kneba M, Stegelmann F, Köhne CA, Lindemann HW, Waller CF, Pfreundschuh M, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Pezzutto A, Schenk M, Brossart P, Geer T, Bildat S, Schäfer E, Hochhaus A, Hasford J.

Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.

10.

Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death.

Lauseker M, Hasford J, Saussele S, Kremers S, Kraemer D, Lindemann W, Hehlmann R, Pfirrmann M; German CML Study Group.

Cancer. 2017 Jul 1;123(13):2467-2471. doi: 10.1002/cncr.30636. Epub 2017 Feb 13.

11.

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.

Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, Hoffmann VS, Gugliotta G, Hehlmann R, Hochhaus A, Hasford J, Baccarani M.

J Cancer Res Clin Oncol. 2017 May;143(5):843-850. doi: 10.1007/s00432-016-2321-2. Epub 2017 Jan 12.

PMID:
28083711
12.

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Schütz C, Inselmann S, Sausslele S, Dietz CT, Mu Ller MC, Eigendorff E, Brendel CA, Metzelder SK, Bru Mmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Xavier Mahon F, Pfirrmann M, Burchert A.

Leukemia. 2017 Apr;31(4):829-836. doi: 10.1038/leu.2017.9. Epub 2017 Jan 11. Erratum in: Leukemia. 2018 Jan 30;:.

PMID:
28074067
13.

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.

Miranda MB, Lauseker M, Kraus MP, Proetel U, Hanfstein B, Fabarius A, Baerlocher GM, Heim D, Hossfeld DK, Kolb HJ, Krause SW, Nerl C, Brümmendorf TH, Verbeek W, Fauser AA, Prümmer O, Neben K, Hess U, Mahlberg R, Plöger C, Flasshove M, Rendenbach B, Hofmann WK, Müller MC, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Saußele S.

Leukemia. 2016 Jun;30(6):1255-62. doi: 10.1038/leu.2016.20. Epub 2016 Feb 9.

14.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

Gratwohl A, Pfirrmann M, Zander A, Kröger N, Beelen D, Novotny J, Nerl C, Scheid C, Spiekermann K, Mayer J, Sayer HG, Falge C, Bunjes D, Döhner H, Ganser A, Schmidt-Wolf I, Schwerdtfeger R, Baurmann H, Kuse R, Schmitz N, Wehmeier A, Fischer JT, Ho AD, Wilhelm M, Goebeler ME, Lindemann HW, Bormann M, Hertenstein B, Schlimok G, Baerlocher GM, Aul C, Pfreundschuh M, Fabian M, Staib P, Edinger M, Schatz M, Fauser A, Arnold R, Kindler T, Wulf G, Rosselet A, Hellmann A, Schäfer E, Prümmer O, Schenk M, Hasford J, Heimpel H, Hossfeld DK, Kolb HJ, Büsche G, Haferlach C, Schnittger S, Müller MC, Reiter A, Berger U, Saußele S, Hochhaus A, Hehlmann R; SAKK; German CML Study Group.

Leukemia. 2016 Mar;30(3):562-9. doi: 10.1038/leu.2015.281. Epub 2015 Oct 14.

15.

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.

Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, Horny HP, Metzgeroth G, Kluger S, Naumann N, Haferlach C, Haferlach T, Valent P, Hofmann WK, Fabarius A, Cross NC, Reiter A.

Leukemia. 2016 Jan;30(1):136-43. doi: 10.1038/leu.2015.284. Epub 2015 Oct 14.

PMID:
26464169
16.

Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.

Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, Hoffmann VS, Castagnetti F, Hasford J, Hehlmann R, Simonsson B.

Leukemia. 2016 Jan;30(1):48-56. doi: 10.1038/leu.2015.261. Epub 2015 Sep 29.

PMID:
26416462
17.

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.

Fabarius A, Kalmanti L, Dietz CT, Lauseker M, Rinaldetti S, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Hanfstein B, Seifarth W, Hänel M, Köhne CH, Lindemann HW, Berdel WE, Staib P, Müller MC, Proetel U, Balleisen L, Goebeler ME, Dengler J, Falge C, Kanz L, Burchert A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Brümmendorf TH, Edinger M, Hofmann WK, Pfirrmann M, Hasford J, Krause S, Hochhaus A, Saußele S, Hehlmann R; SAKK and the German CML Study Group.

Ann Hematol. 2015 Dec;94(12):2015-24. doi: 10.1007/s00277-015-2494-9. Epub 2015 Sep 18.

PMID:
26385387
18.

Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.

Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomäus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Müller MC; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group.

Blood. 2015 Jul 2;126(1):42-9. doi: 10.1182/blood-2015-01-617993. Epub 2015 Apr 27.

19.

Ultra-large scale AFM of lipid droplet arrays: investigating the ink transfer volume in dip pen nanolithography.

Förste A, Pfirrmann M, Sachs J, Gröger R, Walheim S, Brinkmann F, Hirtz M, Fuchs H, Schimmel T.

Nanotechnology. 2015 May 1;26(17):175303. doi: 10.1088/0957-4484/26/17/175303. Epub 2015 Apr 9.

PMID:
25854547
20.

Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death.

Pfirrmann M, Lauseker M, Hoffmann VS, Hasford J.

Ann Hematol. 2015 Apr;94 Suppl 2:S209-18. doi: 10.1007/s00277-015-2316-0. Epub 2015 Mar 27. Review.

PMID:
25814087
21.

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R.

Leukemia. 2015 May;29(5):1123-32. doi: 10.1038/leu.2015.36. Epub 2015 Feb 13.

PMID:
25676422
22.

A multi-state model approach for prediction in chronic myeloid leukaemia.

Lauseker M, Hasford J, Hoffmann VS, Müller MC, Hehlmann R, Pfirrmann M; German CML Study Group.

Ann Hematol. 2015 Jun;94(6):919-27. doi: 10.1007/s00277-014-2246-2. Epub 2014 Dec 3.

PMID:
25465231
23.

Reply to H. Kantarjian et al.

Hehlmann R, Hasford J, Pfirrmann M, Lauseker M, Saußele S, Hochhaus A; Schweizer Arbeitsgemeinschaft für klinische; German CML-Study Group.

J Clin Oncol. 2014 Sep 20;32(27):3078-9. No abstract available.

PMID:
25002729
24.

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.

Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, Schlegelberger B, Saußele S, Dietz CT, Erben P, Hehlmann R, Hasford J, Hochhaus A, Müller MC.

J Cancer Res Clin Oncol. 2014 Nov;140(11):1965-9. doi: 10.1007/s00432-014-1746-8. Epub 2014 Jun 22.

PMID:
24952896
25.

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.

Haematologica. 2014 Sep;99(9):1441-7. doi: 10.3324/haematol.2013.096537. Epub 2014 May 16.

26.

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.

Leukemia. 2014 Oct;28(10):1988-92. doi: 10.1038/leu.2014.153. Epub 2014 May 6.

PMID:
24798484
27.

Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia.

Pfirrmann M, Saussele S, Hochhaus A, Reiter A, Berger U, Hossfeld DK, Nerl C, Scheid C, Spiekermann K, Mayer J, Hellmann A, Lechner K, Falge C, Sayer HG, Bunjes D, Ganser A, Beelen DW, Baldomero H, Schanz U, Heimpel H, Kolb HJ, Hasford J, Gratwohl A, Hehlmann R; Schweizerische Arbeitsgemeinschaft für Klinische Forschung (SAKK); German CML Study Group.

J Cancer Res Clin Oncol. 2014 Aug;140(8):1367-81. doi: 10.1007/s00432-014-1662-y. Epub 2014 Apr 10.

PMID:
24718719
28.

The impact of health care settings on survival time of patients with chronic myeloid leukemia.

Lauseker M, Hasford J, Pfirrmann M, Hehlmann R; German CML Study Group.

Blood. 2014 Apr 17;123(16):2494-6. doi: 10.1182/blood-2013-11-539742. Epub 2014 Mar 12.

29.

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Saußele S, Hochhaus A.

J Clin Oncol. 2014 Feb 10;32(5):415-23. doi: 10.1200/JCO.2013.49.9020. Epub 2013 Dec 2.

PMID:
24297946
30.

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.

Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, Hossfeld DK, Kolb HJ, Hochhaus A, Hasford J, Hehlmann R; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK).

Ann Hematol. 2014 Jan;93(1):71-80. doi: 10.1007/s00277-013-1937-4. Epub 2013 Oct 27.

31.

Comprehensive mutational profiling in advanced systemic mastocytosis.

Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, Kohlmann A, Grossmann V, Meggendorfer M, Horny HP, Valent P, Jawhar M, Teichmann M, Metzgeroth G, Erben P, Ernst T, Hochhaus A, Haferlach T, Hofmann WK, Cross NC, Reiter A.

Blood. 2013 Oct 3;122(14):2460-6. doi: 10.1182/blood-2013-04-496448. Epub 2013 Aug 19.

32.

The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.

Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A, Hellmann A, Prejzner W, Steegmann JL, Mayer J, Indrak K, Colita A, Rosti G, Pfirrmann M.

Leukemia. 2013 Oct;27(10):2016-22. doi: 10.1038/leu.2013.171. Epub 2013 Jun 11.

PMID:
23752173
33.

The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.

Lange T, Ernst T, Gruber FX, Maier J, Cross M, Müller MC, Niederwieser D, Hochhaus A, Pfirrmann M.

Haematologica. 2013 May;98(5):714-7. doi: 10.3324/haematol.2012.068890. Epub 2012 Oct 12.

34.

Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.

Büchner T, Schlenk RF, Schaich M, Döhner K, Krahl R, Krauter J, Heil G, Krug U, Sauerland MC, Heinecke A, Späth D, Kramer M, Scholl S, Berdel WE, Hiddemann W, Hoelzer D, Hehlmann R, Hasford J, Hoffmann VS, Döhner H, Ehninger G, Ganser A, Niederwieser DW, Pfirrmann M.

J Clin Oncol. 2012 Oct 10;30(29):3604-10. doi: 10.1200/JCO.2012.42.2907. Epub 2012 Sep 10.

PMID:
22965967
35.

Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82.

Lauseker M, Pfirrmann M, Hoffmann VS, Hasford J.

Haematologica. 2012 May;97(5):e14-5. doi: 10.3324/haematol.2011.061630. No abstract available.

36.

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Göhring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hänel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saußele S, Hochhaus A; SAKK; German CML Study Group.

Leukemia. 2012 Sep;26(9):2096-102. doi: 10.1038/leu.2012.85. Epub 2012 Mar 26.

PMID:
22446502
37.

The EUTOS CML score aims to support clinical decision-making.

Hoffmann V, Baccarani M, Hasford J, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R.

Blood. 2012 Mar 22;119(12):2966-7. doi: 10.1182/blood-2012-01-402511. No abstract available.

38.

Clinical trials in chronic myeloid leukemia.

Saussele S, Pfirrmann M.

Curr Hematol Malig Rep. 2012 Jun;7(2):109-15. doi: 10.1007/s11899-012-0118-1. Review.

PMID:
22422549
39.

Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial.

Pfirrmann M, Ehninger G, Thiede C, Bornhäuser M, Kramer M, Röllig C, Hasford J, Schaich M; Study Alliance Leukaemia (SAL).

Lancet Oncol. 2012 Feb;13(2):207-14. doi: 10.1016/S1470-2045(11)70326-6. Epub 2011 Dec 22.

PMID:
22197676
40.

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, Hehlmann R; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group.

Blood. 2011 Dec 22;118(26):6760-8. doi: 10.1182/blood-2011-08-373902. Epub 2011 Oct 28.

41.

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia.

Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J.

Leukemia. 2011 Sep;25(9):1433-8. doi: 10.1038/leu.2011.116. Epub 2011 May 20.

PMID:
21597465
42.

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.

Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R.

Blood. 2011 Jul 21;118(3):686-92. doi: 10.1182/blood-2010-12-319038. Epub 2011 May 2.

43.

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hänel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saussele S.

J Clin Oncol. 2011 Apr 20;29(12):1634-42. doi: 10.1200/JCO.2010.32.0598. Epub 2011 Mar 21.

PMID:
21422420
44.

Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial.

Stölzel F, Pfirrmann M, Aulitzky WE, Kaufmann M, Bodenstein H, Bornhäuser M, Röllig C, Kramer M, Mohr B, Oelschlägel U, Schmitz N, Soucek S, Thiede C, Ehninger G, Schaich M; Study Alliance Leukemia.

Leukemia. 2011 Mar;25(3):420-8. doi: 10.1038/leu.2010.279. Epub 2010 Dec 7.

PMID:
21135859
45.

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Müller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R; German CML Study Group.

Blood. 2010 Mar 11;115(10):1880-5. doi: 10.1182/blood-2009-08-237115. Epub 2009 Nov 18.

46.

Shedding of the endothelial glycocalyx during cardiac surgery: on-pump versus off-pump coronary artery bypass graft surgery.

Bruegger D, Rehm M, Abicht J, Paul JO, Stoeckelhuber M, Pfirrmann M, Reichart B, Becker BF, Christ F.

J Thorac Cardiovasc Surg. 2009 Dec;138(6):1445-7. doi: 10.1016/j.jtcvs.2008.07.063. Epub 2009 Feb 4. No abstract available.

47.

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.

Ernst T, Gruber FX, Pelz-Ackermann O, Maier J, Pfirrmann M, Müller MC, Mikkola I, Porkka K, Niederwieser D, Hochhaus A, Lange T.

Haematologica. 2009 Sep;94(9):1227-35. doi: 10.3324/haematol.2009.006981. Epub 2009 Jul 16.

48.

A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.

Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, Kramer M, Dill C, Ehninger G, Schackert G, Krex D.

Ann Oncol. 2009 Jan;20(1):175-81. doi: 10.1093/annonc/mdn548. Epub 2008 Aug 7.

PMID:
18687982
49.

Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia.

Kreil S, Pfirrmann M, Haferlach C, Waghorn K, Chase A, Hehlmann R, Reiter A, Hochhaus A, Cross NC; German Chronic Myelogenous Leukemia (CML) Study Group.

Blood. 2007 Aug 15;110(4):1283-90. Epub 2007 Apr 24.

50.

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia.

Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Löffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A.

Blood. 2007 Jun 1;109(11):4686-92. Epub 2007 Feb 22.

Supplemental Content

Loading ...
Support Center